Members of the Celyad leadership team will provide an overview of the recent breakthroughs in the R&D pipeline, updates on key clinical trials and the Company’s cell therapy manufacturing capabilities. In addition, Celyad will unveil its next-generation NKG2D preclinical program CYAD-02 as well as the Company’s proprietary non-gene edited allogeneic platforms including the CYAD-200 series of shRNA-based CAR-T programs.
Footer
Celyad Oncology
